Showing results (281-290 of 311) with videos related to

Sort By:
Pageof 32
British Journal of Cancer|March 10, 2011
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancerF Bertolini, N Malavasi, L Scarabelli, et al.
British Journal of Cancer|June 30, 2005
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinomaC Bengala, V Guarneri, E Giovannetti, et al.
International Journal of Obesity (2005)|January 11, 2014
Impairment of adipose tissue in Prader-Willi syndrome rescued by growth hormone treatmentT Cadoudal, M Buléon, C Sengenès, et al.
American Journal of Clinical Oncology|February 22, 2000
Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap studyA Ardizzoni, G Antonelli, S Ricci, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2005
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO)C Tibaldi, S Ricci, F Russo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2008
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancerC Bengala, S Bettelli, F Bertolini, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 9, 2000
Effect of high-flux dialysis on the anaemia of haemodialysis patientsF Locatelli, S Andrulli, F Pecchini, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytesL Bonanno, A Pavan, M V Dieci, et al.
Trials|December 18, 2015
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialDenise A Yardley, Adam Brufsky, Robert E Coleman, et al.
British Journal of Cancer|January 8, 2004
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancerF Cappuzzo, F Mazzoni, A Gennari, et al.
Pageof 32